Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes. - Wikidata - wikimedia - TriplyDB

Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes.

Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes.

http://www.wikidata.org/entity/Q34802295

about

Transactivation specificity is conserved among p53 family proteins and depends on a response element sequence code The rebel angel: mutant p53 as the driving oncogene in breast cancer.Quantitative Analysis of NF-κB Transactivation Specificity Using a Yeast-Based Functional Assay Structure-based predictions broadly link transcription factor mutations to gene expression changes in cancers.Identification of new p53 target microRNAs by bioinformatics and functional analysis Primed for cancer: Li Fraumeni Syndrome and the pre-cancerous niche TP53 mutants in the tower of babel of cancer progression.Gene-panel testing of breast and ovarian cancer patients identifies a recurrent RAD51C duplication.Human transcription factors in yeast: the fruitful examples of P53 and NF-кB.EEC- and ADULT-associated TP63 mutations exhibit functional heterogeneity toward P63 responsive sequences.Aggregate penetrance of genomic variants for actionable disorders in European and African Americans.p53, p63 and p73 in the wonderland of S. cerevisiae.Mixed adenocarcinoma, sarcomatoid carcinoma and adenosquamous carcinoma of the prostate: A case report.The dominant-negative interplay between p53, p63 and p73: A family affair.Allele-specific wild-type TP53 expression in the unaffected carrier parent of children with Li-Fraumeni syndrome.TP63 mutations are frequent in cutaneous melanoma, support UV etiology, but their role in melanomagenesis is unclear.Recurrent TP53 missense mutation in cancer patients of Arab descent.Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target.ETV7-Mediated DNAJC15 Repression Leads to Doxorubicin Resistance in Breast Cancer Cells Etoposide-resistance in a neuroblastoma model cell line is associated with 13q14.3 mono-allelic deletion and miRNA-15a/16-1 down-regulation Wild-type p53 oligomerizes more efficiently than p53 hot-spot mutants and overcomes mutant p53 gain-of-function via a "dominant-positive" mechanism Clinical relevance of screening checklists for detecting cancer predisposition syndromes in Asian childhood tumours

P2860

Q27679224-9704B5A0-3061-41C9-82F6-BEBF08325FF8 Q27686765-9D1239D3-C9AD-4C49-A14E-07F00E07C22C Q28546323-DB722469-6B68-4EEE-BA17-10EB79310521 Q34579681-92DD07AF-11B3-4262-A3F6-C01A9C83A503 Q35047617-2EECB508-E4EC-4013-9D66-6EB210649ACF Q35717532-8FEF8740-E41C-4225-A542-F2ED7CB0625D Q38180665-8D35B48D-6484-4DE4-B42C-3093A93005DA Q38627916-03051A57-106C-4526-9499-60CF19FF15D4 Q38967375-398DDFE4-7E44-479F-97AF-2FC1D34FC7DA Q39184926-F5C669D0-8EB1-4FE4-9868-2F83D7D1E27E Q39199102-24209B99-7AC4-4CED-8A64-C1C9D0FF785A Q41339413-BFAB965D-1ECD-432B-86D9-6BBBBD3477D9 Q42067376-B1976D50-F2D0-4149-811B-A9B5946885E5 Q42134524-59DF1C4D-6EEC-4B54-91F1-9A65CB2AB9D8 Q42775929-F9AD5CC7-1C1A-4327-9F71-B2DD8C1F2218 Q46408321-7C0645FD-A0B8-4419-90D2-385CF36085A8 Q51057181-4E7B7118-F82D-471A-9A45-69E045ED9A79 Q55515721-326C3A4A-41DA-4DD1-A594-81669A203E8A Q58416369-981E4FA8-0786-4CFC-BC3E-8C98EAA121E7 Q58743588-DCDAACC8-99C9-4BC6-8401-5CE3743A63B5 Q58789576-BC1A1714-CE88-41C0-952E-9190126A0F6E Q59136672-F5B77B55-E939-4EBE-92A1-2A2392E756A5

P2860

Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes.

http://www.wikidata.org/entity/Q34802295

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Dominant-negative features of ...... ted impact on cancer outcomes.

@ast

Dominant-negative features of ...... ted impact on cancer outcomes.

@en

Dominant-negative features of ...... ted impact on cancer outcomes.

@nl

type

label

Dominant-negative features of ...... ted impact on cancer outcomes.

@ast

Dominant-negative features of ...... ted impact on cancer outcomes.

@en

Dominant-negative features of ...... ted impact on cancer outcomes.

@nl

prefLabel

Dominant-negative features of ...... ted impact on cancer outcomes.

@ast

Dominant-negative features of ...... ted impact on cancer outcomes.

@en

Dominant-negative features of ...... ted impact on cancer outcomes.

@nl

P1433

Q34802295-749BEC73-FC9D-4AEC-8654-BB36C85DD320

P1476

Q34802295-C9EEF774-BF52-4B51-B11C-4096F8346D1D

P2093

Q34802295-32BA9736-65A5-4C9A-B004-794389A59FE9

Q34802295-370C427A-5B6D-4CA5-85F9-0E0BD8CFAA14

Q34802295-48B6EDAC-190E-40F4-AE53-D22C240CD7B8

Q34802295-59B8628F-BA37-401E-A155-DF77D12C95C3

Q34802295-BAA5C4AA-ACAD-4BF6-9F70-ADCFCCB43581

P2860

Q34802295-00548315-A011-436A-B933-18F6C83A449D

Q34802295-032E6958-0DE6-4B3A-BBD9-26487412380F

Q34802295-0449301F-71CD-4D23-9A9D-69D6DBFB0976

Q34802295-0760A980-2849-48E8-818E-31F5F4E0A22B

Q34802295-0A2E7A16-3150-4B5E-A3FF-47A0D6886F5C

Q34802295-100EE84D-1983-414F-8BC0-7ED9636F996F

Q34802295-1C46FF0B-6F6F-4885-8537-E4EC8BC425F8

Q34802295-34EC7E82-8A9F-4ECA-9146-0205A983A427

Q34802295-4352553E-4DF4-41A1-8E77-EFFF5EB69A58

Q34802295-504C108B-DAE9-4206-BFD0-E978CB48D5F0

P304

Q34802295-6145F7F0-4B35-4C4A-B600-4EDEDD10315B

P31

Q34802295-CB2C24D4-C8E4-432A-B9B6-9B805914CEE0

P356

Q34802295-1BEEC17C-06B0-4A9D-BECC-B760E5815D10

P433

Q34802295-95CEE495-3A9F-4452-BE56-865AEF7E1C83

P478

Q34802295-AFA1C514-F3B1-4A29-8CBC-4B23704E3E07

P50

Q34802295-0A8C80FE-68DB-44F5-9F27-D5AFCF04E831

Q34802295-4C7C63E5-27B0-409D-8E35-9AC21C97D4B2

Q34802295-96553989-0F06-4004-968E-DBE54BA18507

Q34802295-98DF2AB3-1872-4563-912E-A26D63EAE48B

Q34802295-CA777C0F-4FC4-4D7A-B572-9A725F693384

P577

Q34802295-35136A52-608C-4452-A20E-2B5EF35702E9

P5875

Q34802295-2BD198CD-9E37-4B8C-A9C4-CBEB23FABEBC

P698

Q34802295-E81221C1-F282-4118-B920-49BC660F16E9

P932

Q34802295-7C4AF73C-449E-4A58-95AE-A53E8370D2BF

P356

1541-7786.MCR-10-0496

P1433

Molecular Cancer Research

P1476

Dominant-negative features of ...... ited impact on cancer outcomes

@en

P2093

Alberto Inga

http://www.w3.org/2001/XMLSchema#string

Chiara Perfumo

http://www.w3.org/2001/XMLSchema#string

David M Umbach

http://www.w3.org/2001/XMLSchema#string

Gilberto Fronza

http://www.w3.org/2001/XMLSchema#string

Michael A Resnick

http://www.w3.org/2001/XMLSchema#string

P2860

Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation

Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database

Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity

Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme.

Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation

A cancer family syndrome in twenty-four kindreds.

A simple p53 functional assay for screening cell lines, blood, and tumors.

Is p53 haploinsufficient for tumor suppression? Implications for the p53+/- mouse model in carcinogenicity testing.

Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis.

Linkage studies in a Li-Fraumeni family with increased expression of p53 protein but no germline mutation in p53.

P304

271-279

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1541-7786.MCR-10-0496

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Alessandra Bisio

P577

2011-02-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49856936

http://www.w3.org/2001/XMLSchema#string

P698

21343334

http://www.w3.org/2001/XMLSchema#string

P932

3077904

http://www.w3.org/2001/XMLSchema#string